JP2007511539A - α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 - Google Patents

α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 Download PDF

Info

Publication number
JP2007511539A
JP2007511539A JP2006540034A JP2006540034A JP2007511539A JP 2007511539 A JP2007511539 A JP 2007511539A JP 2006540034 A JP2006540034 A JP 2006540034A JP 2006540034 A JP2006540034 A JP 2006540034A JP 2007511539 A JP2007511539 A JP 2007511539A
Authority
JP
Japan
Prior art keywords
aat
composition
concentration
surfactant
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006540034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511539A5 (https=
Inventor
マンザー ジェイ． デュラニ，
ハリシュ クマー，
ティモシー クレイガー，
ケン カビング，
バージニア モシャー，
フィリップ ジェイ． バール，
イアン シー． バサースト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2007511539A publication Critical patent/JP2007511539A/ja
Publication of JP2007511539A5 publication Critical patent/JP2007511539A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2006540034A 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法 Pending JP2007511539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52054903P 2003-11-14 2003-11-14
PCT/US2004/038650 WO2005048985A2 (en) 2003-11-14 2004-11-11 Alpha 1-antitrypsin compositions and treatment methods using such compositions

Publications (2)

Publication Number Publication Date
JP2007511539A true JP2007511539A (ja) 2007-05-10
JP2007511539A5 JP2007511539A5 (https=) 2007-12-27

Family

ID=34619481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540034A Pending JP2007511539A (ja) 2003-11-14 2004-11-11 α１−抗トリプシン組成物およびこのような組成物を用いた処置方法

Country Status (12)

Country Link
US (2) US20080312136A1 (https=)
EP (1) EP1684719B1 (https=)
JP (1) JP2007511539A (https=)
AT (1) ATE530165T1 (https=)
AU (1) AU2004290587B2 (https=)
CA (1) CA2545855A1 (https=)
DK (1) DK1684719T3 (https=)
ES (1) ES2375706T3 (https=)
PL (1) PL1684719T3 (https=)
PT (1) PT1684719E (https=)
SI (1) SI1684719T1 (https=)
WO (1) WO2005048985A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510158A (ja) * 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP2013515049A (ja) * 2009-12-22 2013-05-02 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
JP2020019765A (ja) * 2018-08-02 2020-02-06 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 高濃縮アルファ−１プロテイナーゼインヒビターを含む組成物及びそれを得るための方法
JP2022509354A (ja) * 2018-10-23 2022-01-20 ホーグ、ジョージ、エドワード 肺を処置するための組成物および方法
JP2024506718A (ja) * 2021-02-17 2024-02-14 アレコル リミテッド 工学作成二量体タンパク質の安定性を高めるための水溶液組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ES2399449T3 (es) 2006-02-09 2013-04-01 Kamada Ltd. Administración pulmonar de un inhibidor de proteinasa alfa-1
CN102131827A (zh) * 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
PT2503995T (pt) 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
CA2844878C (en) * 2011-12-30 2017-11-28 Grifols, S.A. Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
ES2799153T3 (es) * 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2015191892A2 (en) * 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
US20210085764A1 (en) * 2016-12-22 2021-03-25 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
CA3054267A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
WO2018183705A1 (en) 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
WO2019087184A1 (en) * 2017-10-31 2019-05-09 Kamada Ltd Methods and compositions for reducing lung injury associated with lung transplantation
WO2020163703A1 (en) 2019-02-08 2020-08-13 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
US20210189427A1 (en) * 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2001503781A (ja) * 1996-11-19 2001-03-21 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤
JP2001518518A (ja) * 1997-10-03 2001-10-16 アムジエン・インコーポレーテツド 分泌性白血球プロテアーゼインヒビターの乾燥粉末薬学的組成物
JP2003024076A (ja) * 2001-07-12 2003-01-28 Kirin Brewery Co Ltd Ｔｐｏ変異体タンパク質
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150071A (en) * 1977-08-26 1979-04-17 Respiratory Care, Inc. Nebulizer
IT1105653B (it) * 1978-06-20 1985-11-04 Craighero Margherita Apparecchio aerosolizzatore
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4198969A (en) * 1978-10-06 1980-04-22 Baxter Travenol Laboratories, Inc. Suction-operated nebulizer
US4453542A (en) * 1980-12-08 1984-06-12 Vortran Corporation Vortex-generating medical products
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5218091A (en) * 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
WO1985002346A1 (en) * 1983-11-28 1985-06-06 Vortran Corporation Gas-powered nebulizer
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4940661A (en) * 1984-05-17 1990-07-10 Genentech, Inc. Metallothionein transcription control sequences and use thereof
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4752576A (en) * 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
US5114917A (en) * 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
FR2660509B1 (fr) * 1990-03-29 1993-11-19 Alcatel Cit Etage differentiel de sortie d'equipement electronique.
US5012652A (en) * 1990-09-21 1991-05-07 Carrier Corporation Crankcase heater control for hermetic refrigerant compressors
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
TW282490B (https=) * 1992-12-15 1996-08-01 Ciba Geigy Ag
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP1659173A1 (en) * 1997-10-01 2006-05-24 DSMIP Assets B.V. Protein production process
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999032150A1 (en) * 1997-12-23 1999-07-01 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
WO2000051623A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
EE200200426A (et) * 2000-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6991824B2 (en) * 2000-05-02 2006-01-31 Ventria Bioscience Expression of human milk proteins in transgenic plants
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
FR2832569B1 (fr) * 2001-11-22 2007-04-27 Evolium Sas Procede de transmission de communications dans un systeme de telecommunication de type cellulaire utilisant des bandes de frequences porteuses adjacentes
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503781A (ja) * 1996-11-19 2001-03-21 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤
JP2001518518A (ja) * 1997-10-03 2001-10-16 アムジエン・インコーポレーテツド 分泌性白血球プロテアーゼインヒビターの乾燥粉末薬学的組成物
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2003024076A (ja) * 2001-07-12 2003-01-28 Kirin Brewery Co Ltd Ｔｐｏ変異体タンパク質
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510158A (ja) * 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP2015221835A (ja) * 2009-11-03 2015-12-10 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP2013515049A (ja) * 2009-12-22 2013-05-02 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
JP2020019765A (ja) * 2018-08-02 2020-02-06 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 高濃縮アルファ−１プロテイナーゼインヒビターを含む組成物及びそれを得るための方法
JP7458717B2 (ja) 2018-08-02 2024-04-01 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 高濃縮アルファ－１プロテイナーゼインヒビターを含む組成物及びそれを得るための方法
JP2022509354A (ja) * 2018-10-23 2022-01-20 ホーグ、ジョージ、エドワード 肺を処置するための組成物および方法
JP2024506718A (ja) * 2021-02-17 2024-02-14 アレコル リミテッド 工学作成二量体タンパク質の安定性を高めるための水溶液組成物

Also Published As

Publication number Publication date
EP1684719B1 (en) 2011-10-26
AU2004290587B2 (en) 2010-08-12
ATE530165T1 (de) 2011-11-15
SI1684719T1 (sl) 2012-07-31
PL1684719T3 (pl) 2012-11-30
PT1684719E (pt) 2012-02-03
EP1684719A2 (en) 2006-08-02
WO2005048985A2 (en) 2005-06-02
CA2545855A1 (en) 2005-06-02
AU2004290587A1 (en) 2005-06-02
DK1684719T3 (da) 2012-01-30
US20100286066A1 (en) 2010-11-11
ES2375706T3 (es) 2012-03-05
US20080312136A1 (en) 2008-12-18
WO2005048985A3 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
US20100286066A1 (en) Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions
EP1491208B1 (en) Stabilized liquid pharmaceutical compositions containing TFPI
US20010006939A1 (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
AU2002340183B2 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
AU2002340183A1 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
JP2007528409A (ja) プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
JP6030201B2 (ja) α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP2024509543A (ja) ＡＣＥ２ Ｆｃ融合タンパク質の製剤
AU2004288854B2 (en) Dry recombinant human alpha 1-antitrypsin formulation
US20080286279A1 (en) Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
WO2006113360A2 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110304

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412